ATAI ATAI Life Sciences N.V. Common Shares
7.350USD0.00%Mkt Cap: 2.73B $P/E: —27d ago
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments. The company develops rapid-acting and durable therapies for condition…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap2.73B USD
Enterprise Value2.50B USD
Revenue (TTM)4.47M USD
Gross Profit-70.62M USD
Net Income (TTM)-660.05M USD
Revenue/Share0.01 USD
Last Price7.350 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees99
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-15.31
PEG—
EV/EBITDA-17.79
EV/Revenue560.02
P/S609.54
P/B15.38
EPS (TTM)-2.79
EPS (Forward)-0.48
52W Range
3.26598% of range7.450
52W High7.450 USD
52W Low3.265 USD
Profitability
Gross Margin0.00%
Oper. Margin-2590.43%
EBITDA Margin0.00%
Profit Margin-16142.02%
ROE-297.49%
ROA-225.49%
Growth
Revenue Growth137.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-102.67M USD
CapEx (TTM)10.87M USD
FCF Margin-1669.72%
FCF Yield-2.74%
Net Debt-221.52M USD
Net Debt/EBITDA1.57
Balance Sheet
Debt/Equity0.01
Current Ratio8.58
Quick Ratio8.29
Book Value/Sh0.48 USD
Cash/Share0.61 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.8 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.117 USD
Upside (mean)+10.4%
Target Range7.450 USD – 9.250 USD
7.450+10.4% to mean9.250
# Analysts6
Ownership
Shares Out.370.86M
Float308.41M
Insiders2.18%
Institutions52.30%
Short Interest
Short Ratio2.8d
Short % Float6.11%
Short % Out.5.18%
Shares Short19.20M
Short (prev mo.)19.86M
Technical
SMA 506.898 (+6.6%)
SMA 2004.736 (+55.2%)
Beta1.55
S&P 52W Chg15.78%
Avg Vol (30d)12.33M
Avg Vol (10d)19.62M
Technical Indicators
RSI (14)63.7
MACD0.1523
MACD Signal0.2081
MACD Hist.-0.0558
BB Upper7.442 USD
BB Middle7.319 USD
BB Lower7.197 USD
BB Width3.35%
ATR (14)0.0985 USD
Vol Ratio (20d)0.00x